News
RHHBY
50.54
-2.56%
-1.33
Cue Biopharma names Dominic Borie chief medical officer, head of R&D
PUBT · 14h ago
Weekly Report: what happened at RHHBY last week (0706-0710)?
Weekly Report · 17h ago
Mark Cuban Pushes Back on AI Doctors, Says Healthcare Conglomerates Will 'Delay and Deny' Progress
Benzinga · 19h ago
Ionis extends losses as Roche scraps two partnered studies
Seeking Alpha · 3d ago
Nurix Therapeutics price target raised to $34 from $32 at Truist
TipRanks · 3d ago
Nurix Therapeutics price target raised to $33 from $30 at RBC Capital
TipRanks · 3d ago
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
Reuters · 4d ago
Teva, Polpharma ink licensing pact for biosimilar targeting Roche’s Ocrevus
Seeking Alpha · 4d ago
Illumina names Mike Sullivan chief commercial officer effective July 20
PUBT · 4d ago
Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry
Seeking Alpha · 4d ago
Roche Receives CE Mark For Elecsys IGRA TB Blood Test, Expanding Global Access To Tuberculosis Infection Testing Toward WHO Elimination Targets
Benzinga · 4d ago
Roche wins CE mark for Elecsys IGRA TB blood test to detect latent tuberculosis infection
PUBT · 4d ago
White House weighing contenders for FDA's top job
Seeking Alpha · 5d ago
3 Vanguard ETFs That Pay Reliable Dividends
TipRanks · 5d ago
Quest Diagnostics integrates oncology testing into Flatiron OncoEMR via pilot with American Oncology Network
PUBT · 5d ago
Roche Bobois notified AMF of Roche-Chouchan concert stake at 51.19% of capital, 54.08% voting rights
PUBT · 6d ago
Genentech And Roche Showcase Trontinemab, NLRP3 Inflammasome Research And Blood-Based Diagnostics Across Integrated Pharmaceutical And Diagnostics Portfolio At AAIC
Benzinga · 6d ago
Roche wins CE mark for Elecsys pTau217 Alzheimer’s blood test
PUBT · 6d ago
Roche to present new trontinemab Phase III trial data, blood-test advances at AAIC 2026
PUBT · 6d ago
Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC
Barchart · 07/07 00:00
More
Webull provides a variety of real-time RHHBY stock news. You can receive the latest news about Roche Hldg through multiple platforms. This information may help you make smarter investment decisions.
About RHHBY
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.